Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 127 first isolates · ICU · Skin / wound infection · 2025-02-16 → 2026-02-15
Intensive care unitNo single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 57 % (49 %–66 %)
Best two-drug combination: vancomycin + piperacillin-tazobactam covers 98 % (93 %–99 %)
Take cultures before treatment; consider a combination and discuss with infectious
diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (12 %), Citrobacter freundii (6 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
mecillinam MEC
not for this site0 %
0 %
n = 14
trimethoprim TMP
not for this site0 %
0 %
n = 14
nitrofurantoin NIT
not for this site0 %
0 %
n = 14
Most likely organisms for this profile
Staphylococcus aureus
47 %
Pseudomonas aeruginosa
13 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Citrobacter freundii
6 %
Proteus mirabilis
6 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.